Literature DB >> 24813853

Understanding carbamoyl phosphate synthetase (CPS1) deficiency by using the recombinantly purified human enzyme: effects of CPS1 mutations that concentrate in a central domain of unknown function.

Carmen Díez-Fernández1, Liyan Hu2, Javier Cervera3, Johannes Häberle4, Vicente Rubio5.   

Abstract

Carbamoyl phosphate synthetase 1 deficiency (CPS1D) is an inborn error of the urea cycle that is due to mutations in the CPS1 gene. In the first large repertory of mutations found in CPS1D, a small CPS1 domain of unknown function (called the UFSD) was found to host missense changes with high frequency, despite the fact that this domain does not host substrate-binding or catalytic machinery. We investigate here by in vitro expression studies using baculovirus/insect cells the reasons for the prominence of the UFSD in CPS1D, as well as the disease-causing roles and pathogenic mechanisms of the mutations affecting this domain. All but three of the 18 missense changes found thus far mapping in this domain in CPS1D patients drastically decreased the yield of pure CPS1, mainly because of decreased enzyme solubility, strongly suggesting misfolding as a major determinant of the mutations negative effects. In addition, the majority of the mutations also decreased from modestly to very drastically the specific activity of the fraction of the enzyme that remained soluble and that could be purified, apparently because they decreased V(max). Substantial although not dramatic increases in K(m) values for the substrates or for N-acetyl-L-glutamate were observed for only five mutations. Similarly, important thermal stability decreases were observed for three mutations. The results indicate a disease-causing role for all the mutations, due in most cases to the combined effects of the low enzyme level and the decreased activity. Our data strongly support the value of the present expression system for ascertaining the disease-causing potential of CPS1 mutations, provided that the CPS1 yield is monitored. The observed effects of the mutations have been rationalized on the basis of an existing structural model of CPS1. This model shows that the UFSD, which is in the middle of the 1462-residue multidomain CPS1 protein, plays a key integrating role for creating the CPS1 multidomain architecture leading us to propose here a denomination of "Integrating Domain" for this CPS1 region. The majority of these 18 mutations distort the interaction of this domain with other CPS1 domains, in many cases by causing improper folding of structural elements of the Integrating Domain that play key roles in these interactions.
Copyright © 2014 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  CPS 1 structure; CPS1 deficiency; Hyperammonemia; Inborn errors; Site-directed mutagenesis; Urea cycle diseases

Mesh:

Substances:

Year:  2014        PMID: 24813853     DOI: 10.1016/j.ymgme.2014.04.003

Source DB:  PubMed          Journal:  Mol Genet Metab        ISSN: 1096-7192            Impact factor:   4.797


  16 in total

1.  Carbamoylphosphate synthetase 1 (CPS1) deficiency: clinical, biochemical, and molecular characterization in Malaysian patients.

Authors:  Ernie Zuraida Ali; Mohd Khairul Nizam Mohd Khalid; Zabedah Md Yunus; Yusnita Yakob; Chen Bee Chin; Kartikasalwah Abd Latif; Ngu Lock Hock
Journal:  Eur J Pediatr       Date:  2015-10-06       Impact factor: 3.183

2.  Carbamoyl phosphate synthetase 1 deficiency diagnosed by whole exome sequencing.

Authors:  Guoqing Zhang; Yulin Chen; Huiqun Ju; Fei Bei; Jing Li; Jian Wang; Jianhua Sun; Jun Bu
Journal:  J Clin Lab Anal       Date:  2017-04-26       Impact factor: 2.352

3.  Precision medicine in rare disease: Mechanisms of disparate effects of N-carbamyl-l-glutamate on mutant CPS1 enzymes.

Authors:  Dashuang Shi; Gengxiang Zhao; Nicholas Ah Mew; Mendel Tuchman
Journal:  Mol Genet Metab       Date:  2016-12-08       Impact factor: 4.797

Review 4.  CPS1: Looking at an ancient enzyme in a modern light.

Authors:  Matthew Nitzahn; Gerald S Lipshutz
Journal:  Mol Genet Metab       Date:  2020-10-10       Impact factor: 4.797

5.  Novel Pathogenic Variant (c.580C>T) in the CPS1 Gene in a Newborn With Carbamoyl Phosphate Synthetase 1 Deficiency Identified by Whole Exome Sequencing.

Authors:  Rihwa Choi; Hyung Doo Park; Mina Yang; Chang Seok Ki; Soo Youn Lee; Jong Won Kim; Junghan Song; Yun Sil Chang; Won Soon Park
Journal:  Ann Lab Med       Date:  2017-01       Impact factor: 3.464

6.  Hepatic glutamine synthetase augmentation enhances ammonia detoxification.

Authors:  Leandro R Soria; Matthew Nitzahn; Angela De Angelis; Suhail Khoja; Sergio Attanasio; Patrizia Annunziata; Donna J Palmer; Philip Ng; Gerald S Lipshutz; Nicola Brunetti-Pierri
Journal:  J Inherit Metab Dis       Date:  2019-03-11       Impact factor: 4.982

7.  Defective hepatic bicarbonate production due to carbonic anhydrase VA deficiency leads to early-onset life-threatening metabolic crisis.

Authors:  Carmen Diez-Fernandez; Véronique Rüfenacht; Saikat Santra; Allan M Lund; René Santer; Martin Lindner; Trine Tangeraas; Caroline Unsinn; Pascale de Lonlay; Alberto Burlina; Clara D M van Karnebeek; Johannes Häberle
Journal:  Genet Med       Date:  2016-02-25       Impact factor: 8.822

8.  Neonatal-onset carbamoyl phosphate synthetase I deficiency: A case report.

Authors:  Xiaoyan Yang; Jing Shi; Haihong Lei; Bin Xia; Dezhi Mu
Journal:  Medicine (Baltimore)       Date:  2017-06       Impact factor: 1.889

9.  Structure of human carbamoyl phosphate synthetase: deciphering the on/off switch of human ureagenesis.

Authors:  Sergio de Cima; Luis M Polo; Carmen Díez-Fernández; Ana I Martínez; Javier Cervera; Ignacio Fita; Vicente Rubio
Journal:  Sci Rep       Date:  2015-11-23       Impact factor: 4.379

10.  Novel Neonatal Variants of the Carbamoyl Phosphate Synthetase 1 Deficiency: Two Case Reports and Review of Literature.

Authors:  Beibei Yan; Chao Wang; Kaihui Zhang; Haiyan Zhang; Min Gao; Yuqiang Lv; Xiaoying Li; Yi Liu; Zhongtao Gai
Journal:  Front Genet       Date:  2019-08-22       Impact factor: 4.599

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.